Signal Advisors Wealth LLC Has $1.33 Million Stock Holdings in AbbVie Inc. $ABBV

Signal Advisors Wealth LLC boosted its position in AbbVie Inc. (NYSE:ABBV) by 93.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,830 shares of the company’s stock after acquiring an additional 2,824 shares during the period. Signal Advisors Wealth LLC’s holdings in AbbVie were worth $1,332,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the 2nd quarter valued at about $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie during the 3rd quarter worth approximately $26,000. Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie during the third quarter worth approximately $31,000. Caitlin John LLC acquired a new position in AbbVie in the third quarter valued at approximately $33,000. Finally, Delos Wealth Advisors LLC acquired a new position in AbbVie in the second quarter valued at approximately $39,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on the stock. Evercore lowered their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Barclays started coverage on AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. Finally, Morgan Stanley upped their price objective on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.15.

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by corporate insiders.

AbbVie Stock Performance

ABBV opened at $211.12 on Friday. The firm’s fifty day moving average is $222.06 and its two-hundred day moving average is $224.53. The firm has a market cap of $373.29 billion, a PE ratio of 89.46, a price-to-earnings-growth ratio of 0.72 and a beta of 0.34. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the business earned $2.16 EPS. The firm’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics will present 21 evidence-based e-posters at AMWC 2026, highlighting clinical and real‑world data that support product leadership and could help maintain premium pricing and practitioner demand. Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
• Positive Sentiment: Allergan is promoting a new “Undetectable” era for JUVÉDERM at AMWC, a marketing/product push that may support volume and pricing for AbbVie’s largest aesthetics franchise. Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
• Positive Sentiment: Erste Group nudged up its FY2027 EPS forecast for AbbVie (to $16.16), a small analyst lift that signals growing analyst confidence in longer‑term earnings power. Erste Group Bank upped their FY2027 earnings per share (EPS) estimates for AbbVie
• Positive Sentiment: AbbVie’s official partnership with MLB (seasonal marketing/awareness) can broaden brand visibility for patient and provider audiences and is a supportive commercial catalyst. How AbbVie’s official partnership with MLB will unfold over the course of the season
• Neutral Sentiment: Zacks and other outlets note elevated investor attention on AbbVie and publish comparative takes (e.g., vs. Eli Lilly) — increased search/coverage can raise short-term volatility but also liquidity. Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
• Neutral Sentiment: Coverage labeling AbbVie as a candidate in the psychedelics/psychiatry theme (coverage of bretisilocin acquisition) may attract growth‑oriented investors, but clinical risk and long timelines keep impact uncertain. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Negative Sentiment: Analyst commentary and valuation pieces point to recent share weakness (declines over the past week/month) and ongoing valuation questions despite multi-year gains, which can cap near‑term upside. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.